^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Merkel Cell Carcinoma
    Drug:Bavencio (avelumab) (PD-L1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    European Medicines Agency
    Published date:
    08/31/2020
    Excerpt:
    Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    FDA
    Published date:
    06/30/2020
    Excerpt:
    BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for...Merkel Cell Carcinoma (MCC)...Adults and pediatric patients 12 years and older with metastatic MCC.
    Evidence Level:
    Sensitive: A1 - Approval
    Source:
    Pfizer Press Release
    Title:

    BAVENCIO (AVELUMAB) APPROVED FOR MERKEL CELL CARCINOMA IN JAPAN

    Published date:
    09/27/2017
    Excerpt:
    Merck KGaA, Darmstadt, Germany, and Pfizer Inc. (NYSE: PFE) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved BAVENCIO® (avelumab, genetically recombinant Injection 200mg/mL for intravenous use) as the first and only treatment indicated for curatively unresectable Merkel cell carcinoma (MCC), a rare and aggressive cancer, in Japan.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NICE
    Title:

    Avelumab for untreated metastatic Merkel cell carcinoma

    Published date:
    04/21/2021
    Excerpt:
    Avelumab is recommended as an option for treating metastatic Merkel cell carcinoma in adults who have not had chemotherapy for metastatic disease.
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    10/02/2019
    Excerpt:
    NCCN Recommendations for Selection of Systemic Therapy for Distant Metastatic Disease…3 checkpoint immunotherapies (avelumab, pembrolizumab, and nivolumab) recommended by NCCN as options for metastatic MCC…